Xvivo Perfusion releases transcript of Q2 2026 earnings call

  • Xvivo Perfusion released a transcript of its Q2 2026 earnings call attended by CEO Christoffer Rosenblad and CFO Kristoffer Nordstrom.
  • Net sales SEK 239 million, organic growth 36%; EBITDA SEK 45 million, 19% margin; gross margin 71%.
  • Operating cash flow SEK 63 million; investing cash flow minus SEK 68 million; cash position SEK 305 million.
  • Management expects to submit the U.S. heart PMA file to the FDA during Q3, pending validation and product-aging data.
  • EVLP OPO hub pilot expanded to three onboarded OPOs, 45 in pipeline; first OPO ran about 20 procedures in H1.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xvivo Perfusion AB published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.